Sanofi-Aventis and the FDA have notified healthcare professionals of changes to the warnings and overdose sections of the prescribing information for desipramine hydrochloride (Norpramin). The new safety information states that extreme caution should be used when this drug is given to patients who have a family history of sudden death, cardiac dysrhythmias, and cardiac conduction disturbances; and that seizures precede cardiac dysrhythmias and death in some patients.